Formulary
Belatacept: Indications, Dosing, Side Effects and Interactions
Belatacept clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Belatacept: Indications, Dosing, Side Effects and Interactions
Belatacept clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Prophylaxis of graft rejection in adults undergoing renal transplantation who are seropositive**
- **Adult** (By Intravenous Infusion): for the Epstein-Barr virus (consult product literature).
Cautions
Increased risk of acute graft rejection-with tapering of corticosteroid, particularly in patients with high immunologic risk; increased risk of infection; latent and active tuberculosis; risk factors for post-transplant lymphoproliferative disorder
Side effects
Common or very common Acidosis; alopecia; anaemia; angina pectoris; arrhythmias; arterial fibrosis; cataract; chest pain; constipation; cough; Cushing's syndrome; decreased leucocytes; diabetes mellitus; diarrhoea; dizziness; dyslipidaemia; dyspnoea; ear pain; electrolyte imbalance; embolism and thrombosis; eye erythema; fatigue; fever; fluid imbalance; gastrointestinal discomfort; gastrointestinal disorders; haemorrhage; headaches; healing impaired; heart failure; hepatic disorders; hypercapnia; hyperglycaemia; hypertension; hypoproteinaemia; hypotension; increased risk of infection; intervertebral disc disorder; joint disorders; lethargy; leucocytosis; lymphocele; malaise; muscle complaints; muscle weakness; nausea; neoplasms; nerve disorders; neutropenia; oral disorders; oropharyngeal complaints; osteoarthritis; pain; paraesthesia; peripheral oedema; polyomavirus infections; pulmonary oedema; red blood cell abnormalities; renal disorders; renal tubular necrosis; respiratory disorders; scrotal disorders; sepsis; shock; skin reactions; stroke; sweat changes; syncope; thrombocytopenia; tinnitus; transplant rejection; tremor; urinary disorders; urine abnormalities; vascular disorders; ventricular hypertrophy; vertigo; vesicoureteric reflux; vision disorders; vomiting; weight changes Uncommon Acute coronary syndrome; adrenal insufficiency; agranulocytosis; alkalosis; anxiety; aortic valve disease; appetite decreased; arterial stenosis; atrioventricular block; attention deficit/hyperactivity disorder; bone disorders; bone fracture; breast mass; broken nails; cervical dysplasia; cholelithiasis; cognitive disorder; demyelination; depression; diabetic foot; diabetic ketoacidosis; disease recurrence; dysphonia; encephalopathy; endocarditis; eye inflammation; facial paralysis; facial swelling; feeling hot; fibrosis; flushing; haemolysis; hair changes; hearing impairment; hemiparesis; hypercoagulation; hypogammaglobulinaemia; infertility; inflammation; infusion related reaction; intermittent claudication; intracranial pressure increased; lymphangitis; memory loss; mood altered; nephritis; nephrosclerosis; pancreatitis; penile ulceration; pneumonitis; post procedural haematoma; procedural complications; progressive multifocal leukoencephalopathy (PML); pulmonary hypertension; renal tubular atrophy; restless legs; seasonal allergy; seizure; sexual dysfunction; sleep apnoea; sleep disorders; taste altered; tendon rupture; testicular pain; ulcer; vitamin D deficiency; vulvovaginal disorders; wound dehiscence Side-effects, further information Side effects are reported when used in combination with basiliximab, mycophenolate mofetil and corticosteroids.
Interactions
**Other interactions (3):**
- Belatacept appears not to have any relevant direct effects on cytokine levels in liver transplant recipients or in healthy volunteers.
- At a given dose of MMF, MPA exposure is approximately 40% higher with belatacept coadministration than with ciclosporin coadministration.
- Therefore, during treatment with belatacept, vaccinations may be less effective although this has not been studied in clinical trials.
Pregnancy
Use only if essential.
Breast feeding
Avoid-no information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Belatacept in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

